Key Insights

Highlights

Success Rate

86% trial completion

Published Results

17 trials with published results (32%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

9.4%

5 terminated out of 53 trials

Success Rate

86.1%

-0.4% vs benchmark

Late-Stage Pipeline

8%

4 trials in Phase 3/4

Results Transparency

55%

17 of 31 completed with results

Key Signals

17 with results86% success

Data Visualizations

Phase Distribution

47Total
Not Applicable (10)
Early P 1 (5)
P 1 (15)
P 2 (13)
P 3 (4)

Trial Status

Completed31
Withdrawn6
Recruiting6
Terminated5
Active Not Recruiting2
Unknown2

Trial Success Rate

86.1%

Benchmark: 86.5%

Based on 31 completed trials

Clinical Trials (53)

Showing 20 of 20 trials
NCT04811703Phase 1Recruiting

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer

NCT05429970Not ApplicableRecruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

NCT05659381Phase 3Recruiting

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT04204811Not ApplicableActive Not Recruiting

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

NCT02111941Early Phase 1Completed

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT03188432Phase 2Completed

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03154190Not ApplicableCompleted

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT02124421Phase 2Active Not Recruiting

HOT: HIPEC in Ovarian Cancer as Initial Treatment

NCT01606241Phase 1Completed

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT05410717Phase 1RecruitingPrimary

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

NCT00194714Phase 1Completed

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

NCT06315270Not Yet Recruiting

To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer

NCT05961124Phase 2Recruiting

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

NCT05025748Not ApplicableCompleted

Ask Questions (ASQ):Implementation of a Communication Intervention

NCT03811899Not ApplicableCompleted

18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)

NCT03029611Phase 2Terminated

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

NCT01551745Phase 2Completed

Salvage Ovarian FANG™ Vaccine + Bevacizumab

NCT03297489Early Phase 1Completed

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

NCT04267575Not ApplicableUnknown

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

NCT02441140Not ApplicableTerminated

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Scroll to load more

Research Network

Activity Timeline